Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.81%, 18.09%, and 16.45% respectively [1][2] - The companies with the largest increase in short positions are Lens Technology (06613), Shangmei Co., Ltd. (02145), and Youran Dairy (09858), with increases of 2.38%, 0.97%, and 0.64% respectively [1][2] - The companies with the largest decrease in short positions are Sanhua Intelligent Control (02050), SenseTime-W (00020), and Ganfeng Lithium (01772), with decreases of -1.93%, -1.22%, and -1.06% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Hengrui Medicine (01276) at 15.21%, ZTE Corporation (00763) at 14.26%, and Ping An Insurance (02318) at 14.10% [2] - The companies with the most significant increase in short ratios also include China Merchants Bank (03968) at 7.77% and Laopu Gold (06181) at 4.27% [2] - The companies with the most significant decrease in short ratios also include Zhongchuang Zhiling (00564) at 4.15% and Weichai Power (02338) at 4.93% [2]

| 申万菱信医药先锋股票A(005433) | | | | --- | --- | --- | | 单位净值(2026-01-08) | 累计净值 | | | 0.4934 0.12% | 0.4934 | | | 近1月:2.03% | 沂3月: -6.46% | 沂6日: -9 13% | | 沂1年:-6.52% | 沂3年:-38.88% | 成立来:-50.66% | | 申万菱信医药先锋股票C(015171) | | | | 单位净值(2026-01-08) | 累计净值 | | | 0.4847 0.12% | 0.4847 | | | 沂1月:1.98% | 近3月: -6.77% | 近6日: -9.52% | | 沂1年: - 7.09% | 近3年:-39.74% | 成立来:-40.17% | 来源：同花顺 中国经济网北京1月9日讯 据同花顺数据显示，在刚过去的2025年，申万菱信医药先锋股票C、申万 菱信医药先锋股票A以-17.81%、-17.29%的表现垫底全年普通股票型基金业绩排行榜。 (责任编辑：康博) 资料显示，申万菱信医药先锋股票A/C分别成立于2020年11月和2022年 ...

Group 1 - The core viewpoint of the news highlights the performance and growth of the Tianhong Innovation Drug ETF (517380), which has seen significant trading activity and net inflows, indicating strong investor interest in the innovative pharmaceutical sector [1] - As of January 8, the Tianhong Innovation Drug ETF reached a new high with a total scale of 1.597 billion yuan and 1.980 billion shares outstanding, reflecting robust market demand [1] - The ETF tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID), which includes a diverse selection of 50 leading innovative pharmaceutical companies, with a composition of 40% Hong Kong stocks and 60% A-shares [1] Group 2 - Notable achievements in the innovative pharmaceutical sector include Shiyao Group's R&D expenses of 4.185 billion yuan for the first three quarters of 2025, focusing on ADC, GLP-1, and small nucleic acid pipelines, with total authorized amounts exceeding 9.7 billion USD [2] - BeiGene is projected to achieve a profit of 200 million USD in 2025, with expectations of reaching 600-800 million USD in 2026, as several solid tumor drugs enter critical clinical stages [2] - Three Life Sciences has partnered with Pfizer for a 6 billion USD dual antibody licensing deal, receiving an upfront payment of 1.4 billion USD, with 20 clinical studies planned for 2026 [2]

Group 1 - The Hang Seng Index closed down 0.94%, with the technology sector experiencing the largest decline [1] - The Hang Seng Technology Index fell by 1.81%, with notable drops from BYD Co. Ltd. (-3.93%), Alibaba (-3.25%), and NetEase (-2.88%) [3] - The Hang Seng Bank Index also saw a decline of 1.1%, with Standard Chartered down 2.43% and China Construction Bank down 1.42% [3] Group 2 - The Hang Seng Healthcare Index rose by 2.47%, driven by significant gains from companies like CanSino Biologics (+7.31%) and 3SBio (+7.16%) [3] - Other healthcare stocks such as WuXi Biologics and Innovent Biologics also saw increases of 5.92% and 5.38% respectively [3] - More than ten healthcare stocks recorded gains exceeding 3% [3]

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 | 代码 名称 | | 12月复权单位 累计单位 | | | --- | --- | --- | --- | | | 净值增长率8 净值元 | | | | 513060. SH 博时恒生医疗保健(QDII-ETF) | -10.17 | 0.59 | 63.02 2021-03-18 万琼 | 来源：同花顺 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 （责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@s ...

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，易方达全球医药行业混合(QDII)C/A(人民币份额)单月下跌10.12%、10.11%。 截至2025年三季度末规模为20.67亿元。 | 代码 名称 | 区间复权单 累计单位净基金规模[3基金成立日基金经理(基金投资类投 | | --- | --- | | 019035.0F 易方达全球医药行业混合(QDII)C(人民币份额) | -10.12 1.22 7.49 2023-11-1 杨桢霄 混合型 QI | | 008284.0F 易方达全球医药行业混合(QDII)A(人民币份额) | -10.11 1.23 13.18 2020-01-2 杨桢霄 | (责任编辑：何潇) 2025年三季度前十大重仓股为前十大重仓股分别为复宏汉霖、信达生物、科伦博泰生、映恩生物、乐普生物、康诺亚、中国生物制药、翰森制药、三生 制、荣昌生物。该基金目前由基金经理杨桢霄管理，杨桢霄现任易方达基金管理有限公司基金经理。曾任易方达基金管理有限公司投资经理、行业研究员、 基金经理助理。 ...

(责任编辑：华青剑) 来源：同花顺 中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，广发中证香港创新药 (QDII-ETF)单月下跌11.16%。截至2025年三季度末规模为138.75亿元。 2025年三季度前十大重仓股为信达生物、百济神州、药明生物、康方生物、中国生物制药、石药集 团、三生制药、药明康德、翰森制药、科伦博泰生物。基金经理刘杰现任广发基金管理有限公司指数投 资部总经理助理、基金经理。 | 代码 名称 | 12月复权单位 累计单位 规模亿元 基金成立日 基金经理 | | --- | --- | | | 净值增长率8 净值元 | | 513120. SH 广发中证香港创新药(QDII-ETF) | -11.16 1.20 234.03 2022-07-01 刘杰 | ...

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 来源：同花顺 (责任编辑：康博) 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 | 代码 名称 | 12月复权单位 累计单位 规模亿元 基金成立日 基金经理 | | --- | --- | | | 净值增长率8 净值元 | | 513060.SH 博时恒生医疗保健(QDII-ETF) | -10.17 0.59 63.02 2021-03-18 万琼 | ...

Group 1 - The core message of the news is that China's National Medical Products Administration (NMPA) will enhance support for innovative drugs with new mechanisms and targets throughout the entire process from communication, clinical trials, registration, to review and approval, promoting "China's first launch" of innovative drugs [1][5] - By 2025, it is projected that 76 innovative drugs will be approved for market in China, with 80.85% of chemical drugs being domestic innovations and 91.3% of biological products being domestically developed [5][6] - The internationalization of China's pharmaceutical industry is advancing, with cumulative overseas licensing transactions for innovative drugs exceeding $130 billion, marking a shift from a "generic drug manufacturing powerhouse" to an "innovative drug exporting powerhouse" [6] Group 2 - The A-share market is seeing a strong performance in innovative drug concept stocks, with companies like Beibite-U and Hongbo Pharmaceutical experiencing significant price increases [2][3] - As of the end of 2025, the total market capitalization of 158 innovative drug concept stocks in the A-share market reached 3.42 trillion yuan, with several companies achieving over 100 billion yuan in market value [12][14] - The innovative drug sector is expected to remain a key investment theme in 2026, with a focus on clinical progress and data validation for pipelines that have already entered overseas markets [12][16]

Core Viewpoint - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing a rally, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, gaining over 2% and surpassing the 60-day moving average [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and rose by 2.02% to a price of 0.555, with a trading volume of 95,100 shares [2]. - Major constituents of the ETF include: - InnoCare Pharma-B (映恩生物-B) up over 6% - Hutchison China MediTech (和黄医药) up over 4% [1][2]. Group 2: Regulatory and Company Developments - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed overseas marketed original and generic drugs in China [1][3]. - Recent announcements from innovative drug companies include: - Sinopharm's SAL0145 injection clinical trial application accepted by NMPA [3]. - Hengrui Medicine's approval for its innovative drug Rilapladib injection [3]. Group 3: Investment Sentiment and Recommendations - Recent reports from securities firms such as Pacific Securities, Guotai Junan, and Industrial Securities are bullish on the innovative drug sector, emphasizing the importance of "innovation + internationalization" as a core theme for the pharmaceutical sector by 2026 [3][4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three key advantages: 1. Pure and comprehensive coverage of innovative drug R&D companies [4]. 2. High concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [5]. 3. Controlled risks through forced de-weighting of less liquid constituent stocks [4].